Lupin Q2 FY27 investor presentation: sales up 14.0% YoY, EBITDA margin down to 25.1%
Q2 FY27 sales up 14.0% to INR 77,855 mn but EBITDA down 8.4% and net income down 21.8%, EBITDA margin at 25.1%.
By ScoutQuest · · 1 min read
- Q2 FY27 Net Sales
- INR 77,855 mn, up 14.0% year on year
- Q2 FY27 EBITDA
- INR 19,574 mn, down 8.4%; EBITDA margin 25.1% vs 31.3%
- Q2 FY27 Net Income
- INR 11,553 mn, down 21.8%
- Period
- Q2 FY27 and H1 FY27
- Positioning
- A global pharma that says it is #3 in the US by prescriptions (~5.0% Gx TRx volume share), #2 in Indian respiratory and #3 in cardiac and diabetes care, with India, North America, EMEA, APAC, LATAM, ROW and API businesses.
📉 Q2 FY27 net sales rose 14.0% year on year to INR 77,855 mn, but EBITDA fell 8.4% to INR 19,574 mn and net income 21.8% to INR 11,553 mn; EBITDA margin dropped to 25.1% from 31.3% and other operating income fell 80.7% to INR 418 mn.
📉 For H1 FY27 the company reports net sales of INR 160,028 mn, up 23.1%, EBITDA of INR 44,209 mn, up 17.0% at a 27.6% margin, and net income of INR 25,703 mn, down 4.7%; by market India rose 15% to INR 23,836 mn and North America 10% to INR 31,696 mn, while LATAM fell 30% and ROW 4%.
📉 US sales of US$ 317 mn were up 1% year on year but 13% lower quarter on quarter; the presentation attributes the quarter to increased competition and loss of exclusivity on key products, partially offset by seasonal demand and volume growth in select products.
🔬 Management states it plans to file 15+ ANDAs and launch ~15 products in the US in FY27, launch 20+ products in India in FY27, and targets 100+ new product launches with ~70%+ of that revenue from complex products by FY32 and at least six biosimilars by FY32.
Also from Lupin
Lupin Q2 FY2027: EBITDA falls 10.7% YoY to INR 21,712 Mn, EBITDA margin narrows 770 bps to 27.9%
4 Nov 2026
Q2/H1 FY27 results approved; consolidated net profit ₹11,553.0 million, standalone loss ₹59.1 million
4 Nov 2026
Lupin Ltd press release
3 Nov 2026
More numbers
- Net sales, Q2 FY2777,855 (INR mn)
- EBITDA, Q2 FY2719,574 (INR mn)
- Net income after NCI, Q2 FY2711,553 (INR mn)
- EBITDA margin, Q2 FY2725.1%
- Net sales YoY growth, Q2 FY2714.0%
- Net income YoY growth, Q2 FY27-21.8%
- Net sales, H1 FY27160,028 (INR mn)
- India sales, Q2 FY2723,836 mn
- North America sales, Q2 FY2731,696 mn
- R&D spend, Q2 FY276,181 (INR mn)
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.